According to Morgan Keegan, Epocrates EPOC price target is lowered to $16.
Morgan Keegan said that EPOC has a unique footprint of 340,000 physicians that use its handheld drug reference software. “Our new December quarter estimate is $0.04 on $28.5 million versus the consensus of $0.07 on $32.3 million.”
Epocrates closed yesterday at $8.39.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in